Antibodies News and Research

RSS

NIH grant supports Oklahoma researcher investigating protein linked to lupus

For the millions of people living with lupus – a chronic autoimmune disease that can damage the kidneys, brain and other vital organs – treatment options remain limited and often come with serious side effects.

4 Mar 2026

Natural fungal supplement strengthens vaccine protection without increasing side effects

Researchers at University California San Diego School of Medicine have found that a natural fungal supplement taken at the time of COVID-19 vaccination reduced short-term vaccine side effects and helped antibodies - the body's natural immune defenders - last longer in people who had not previously been exposed to the virus.

4 Mar 2026

Gut bacteria may explain differences in peanut allergy reactions

One of the big mysteries in food allergy is why two people with similar levels of peanut specific antibodies can react so differently. It turns out the answer may be in the mouth and gut's bacteria.

3 Mar 2026

New blood biomarker may detect Alzheimer’s pathology more accurately

Researchers compared total plasma pTau217 with a brain-derived pTau217 assay to determine which better identifies Alzheimer’s disease–related amyloid and tau pathology. Brain-derived pTau217 showed strong diagnostic performance and appeared less affected by kidney dysfunction, supporting its potential as a more specific blood biomarker for Alzheimer’s disease.

3 Mar 2026

The surprising neurological benefits of GLP-1s

For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such as diabetes and weight loss, was associated with fewer emergency department visits and hospitalizations overall, and with less need for medications used to stop and prevent migraine attacks, according to a preliminary study released March 1, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online.

2 Mar 2026

Engineered proteins track gene expression in living primate brains

Gene therapy has been successfully used to treat a number of diseases, including immune deficiencies, hereditary blindness, hemophilia and, recently, Huntington's disease, a fatal neurological disorder.

27 Feb 2026

New structural insights pave way for hantavirus vaccines

Hantaviruses, transmitted from rodents to people, have a death rate approaching 40%. They're found around the world, and because there are no approved vaccines or treatments, they're among the pathogens of highest concern for future pandemics.

27 Feb 2026

No evidence connects tick bites to chronic health problems

When researchers studied Norwegians who thought tick bites caused their chronic health problems, they found no objective evidence linking the symptoms to ticks.

25 Feb 2026

Mizzou tackles rising alpha-gal syndrome cases with research and outreach

The University of Missouri is on the front lines of helping patients with alpha-gal syndrome - a potentially life-threatening red-meat allergy caused by lone star tick bites.

24 Feb 2026

Viral RNA modifications trigger celiac inflammation

An EHU study indicates that a drug already approved for use in humans could help to reduce the inflammation associated with celiac disease.

24 Feb 2026

Throwing cancer-driving proteins in the cellular trash

When cancer-driving proteins resist various treatments, Northwestern University scientists have uncovered a new solution. Don't fight them - throw them in the cellular trash.

24 Feb 2026

Bruker advances Functional Proteomics 2.0 with timsOmni™ mass spectrometry proteoform analysis for deeper insights into disease biology

Bruker Corporation today announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional proteoforms and PTM-resolved peptide variants.

From Bruker Daltonics 24 Feb 2026

Discovery offers hope for reducing immune-related heart risks in cancer patients

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives.

20 Feb 2026

New technique synthesizes non-natural amino acids for advanced peptide therapeutics

Ozempic has been making headlines for its remarkable success in treating obesity and diabetes. Yet it is just one in a rapidly growing class of drugs called peptide therapeutics that sits between small molecules (like aspirin) and biologics (like antibodies).

20 Feb 2026

Blood markers can indicate people at risk of developing ulcerative colitis

Researchers at örebro University have identified blood markers that can indicate who is at risk of developing ulcerative colitis - a chronic inflammatory bowel disease - later in life.

20 Feb 2026

Fred Hutch scientists reach crucial milestone in blocking Epstein Barr virus

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.

17 Feb 2026

Infant bifidobacteria may protect against childhood allergies

Certain gut bacteria in infants may reduce the risk of developing allergies later in childhood. This is the finding of new research from the ALADDIN study at Karolinska Institutet, published in Nature Microbiology.

16 Feb 2026

Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation

Intranasal boosting after prior intramuscular COVID vaccination induced strong mucosal IgA responses in a small human cohort. These antibodies showed markedly enhanced neutralising activity against Omicron variants and evidence of immune memory reprogramming toward mucosal protection.

15 Feb 2026

Antibody feedback reshapes B cell selection during immune response

A collaborative study published in Immunity from the Batista Lab and Liu Lab at the Ragon Institute, together with the Schief Lab at Scripps Research Institute, has uncovered a previously unrecognized mechanism that shapes how immune cells are selected during an immune response.

13 Feb 2026

Novel antibody 007 targets the elusive HIV envelope epitope

HIV-1 can be neutralized by antibodies which bind to vulnerable structures on the virus surface. One such vulnerable site is the so-called V3 glycan site of the viral envelope protein.

13 Feb 2026